The importance of the kidney's role in glucose homeostasis has gained wider understanding in recent years. Consequently, the development of a new pharmacological class of anti-diabetes agents targeting the kidney has provided new treatment options for the management of type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT2) inhibitors, such as dapagliflozin, canagliflozin, and empagliflozin, decrease renal glucose reabsorption, which results in enhanced urinary glucose excretion and subsequent reductions in plasma glucose and glycosylated hemoglobin concentrations. Modest reductions in body weight and blood pressure have also been observed following treatment with SGLT2 inhibitors. SGLT2 inhibitors appear to be generally well tolerated, and have been used safely when given as monotherapy or in combination with other oral anti-diabetes agents and insulin. The risk of hypoglycemia is low with SGLT2 inhibitors. Typical adverse events appear to be related to the presence of glucose in the urine, namely genital mycotic infection and lower urinary tract infection, and are more often observed in women than in men. Data from long-term safety studies with SGLT2 inhibitors and from head-to-head SGLT2 inhibitor comparator studies are needed to fully determine their benefit-risk profile, and to identify any differences between individual agents. However, given current safety and efficacy data, SGLT2 inhibitors may present an attractive option for T2DM patients who are failing with metformin monotherapy, especially if weight is part of the underlying treatment consideration. Keywords: anti-diabetes agents, efficacy, hyperglycemia, safety, sodium glucose co-transporter type 2 inhibitors, type 2 diabetes mellitus
Renal glucose handling in the kidney in glucose-tolerant individuals
The human kidney regulates glucose homeostasis via gluconeogenesis, glucose uptake from the circulation, and by glucose reabsorption from the urine filtered in the renal glomeruli. 1 
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Nauck rate of 260-350 mg/min/1.73 m, 2, 3 which is equivalent to a plasma glucose concentration of approximately 200 mg/dL (11.0 mmol/L). 4 The plasma glucose concentration at which Tm glucose is reached is known as the renal threshold for glucose excretion.
Glucose reabsorption from the glomerular filtrate is mediated by sodium glucose co-transporter (SGLT) proteins in a process that is independent of insulin ( Figures 1 and 2) , unlike the action of the major facilitative glucose transporter (GLUT) GLUT4 that is responsible for glucose uptake into insulin-sensitive tissues, such as adipose tissue and muscle. SGLTs are membrane-bound proteins that actively transport glucose against its concentration gradient and, thus, require an energy source to drive the sodium pump. 5 Details of the SGLT family are summarized in Table 1 . 5 Around 90% of filtered renal glucose is reabsorbed in the brush-border of cells in the first segment of the proximal convoluted tubule by SGLT2, a low-affinity, high-capacity transporter, and the remaining 10% is removed in the distal straight segment by SGLT1, a related high-affinity, low-capacity transporter. 5, 6 SGLT1 is also extensively expressed in the small intestine where it has a significant role in glucose absorption. 5 A second group of glucose transporters, the facilitative glucose transporters or GLUTs, then enable the passive diffusion of glucose from the basolateral membrane of cells in the proximal convoluted tubule into the bloodstream, mainly via GLUT2 and to a minor degree via GLUT1. [5] [6] [7] SGLT2 is encoded by the SLC5A2 gene, and a range of loss-of-function mutations in this gene results in the rare disorder of familial renal glucosuria. 8 Familial renal glucosuria is characterized by UGE in the presence of normal plasma glucose concentrations, without any signs of renal tubular dysfunction. 8 Homozygous mutations in the gene encoding SGLT2 result in significant UGE (.10-100 g/1.73 m 2 /day), whereas heterozygous mutations generally result in lower degrees of UGE (,10 g/1.73 m 2 /day). 8 Nevertheless, most individuals affected by familial renal glucosuria are asymptomatic and only rarely suffer from hypoglycemia or hypovolemia, 8 and most of the commonly cited descriptions of this syndrome do not mention an increased risk of genito-urinary infections. In comparison, loss-of-function mutations in the gene encoding SGLT1, SLC5A1, cause glucose-galactose malabsorption in the gut, 9 with little or no glucosuria, which results in severe watery diarrhea in affected newborns; 9 however, dietary tolerance to glucose appears to develop in adulthood, possibly due to development of gastrointestinal flora that aid in its metabolization. 10 
Renal glucose handling in the kidney of an individual with diabetes mellitus
Individuals with type 2 diabetes mellitus (T2DM) have increased renal glucose output in the post-absorptive state, causing increased release of glucose into the blood not only Notes: Glucose and sodium (1:1) enter the renal tubule cells with assistance from glucose transport proteins. Active transport of glucose across the luminal membrane occurs via SGLT2 (and SGLT1) and is driven by coupling glucose transport with sodium co-transport. Glucose then diffuses passively across the basolateral membrane, facilitated by GLUT2 (and GLUT1). Abbreviations: GLUT, facilitative glucose transporter; Na + , sodium; SGLT, sodium glucose co-transporter. from the liver, but also with a significant contribution by the kidneys. 11 Greater postprandial elevation of renal glucose release is also observed in individuals with T2DM versus those with normal glucose tolerance. 12 Moreover, renal glucose uptake is increased in both post-absorptive and postprandial states in individuals with T2DM versus nondiabetic individuals. 11, 12 As demonstrated in an early study of individuals with type 1 DM (T1DM), hyperglycemia may occur without the expected degree of glucosuria, resulting from increased glucose reabsorption from the glomerular filtrate: the mean Tm glucose was reported to be up to 20% higher in individuals with T1DM than in healthy individuals. 13 In addition, increased expression and activity of SGLT2 mRNA and protein have been demonstrated in vitro. 14, 15 There may also be over-expression of SGLT1 in the gastrointestinal tract in patients with diabetes. 16 A recent study also demonstrated a change in renal glucose kinetics in response to SGLT2 inhibition in healthy subjects and those with T2DM, 17 whereby administration of the SGLT2 inhibitor dapagliflozin (10 mg/day for 7 days) reduced Tm glucose by approximately 55% in both groups. 17 Moreover, dapagliflozin reduced the plasma glucose threshold at which glucose excretion began to concentrations well below fasting levels (ie, 4.7-6.0 mmol/L [85-108 mg/dL]) in both groups: glucosuria threshold was reduced to 1.2±2.6 mmol/L (21±46 mg/dL) in subjects with T2DM and to 2.0±2.2 mmol/L (37±40 mg/dL) in healthy subjects (P,0.001 for both groups). 17 In healthy glucose-tolerant individuals, having a Tm glucose of approximately 200 mg/dL (11.0 mmol/L) that is well above the normal filtered glucose load of approximately 100 mg/dL (5.5 mmol/L) allows the kidney to conserve this energy source for future use when glucose availability is scarce; however, this process may become maladaptive in Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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Nauck individuals with DM. 18 Instead of excreting excess glucose into the urine in the presence of hyperglycemia, the kidneys of a diabetic person continue to reabsorb glucose, due to an elevation of the Tm glucose. 18 Consequently, hyperglycemia remains uncorrected and contributes to the ensuing problem of glucose toxicity. Thus, if SGLT2 activity promotes glucose conservation and hinders normalization of plasma glucose levels in DM, it is postulated that inhibition of SGLT2 might decrease the threshold for UGE (glucosuria) and reduce hyperglycemia 18, 19 
Early SGLT2 inhibitors
Early investigations into renal glucose handling were carried out on phlorizin (Figure 3 ), a naturally occurring glucoside found in the root bark of fruit trees. 20 Studies from the 1950s revealed that phlorizin blocked sugar transport in several tissues, including the kidney and small intestine. 21 This was later found to be due to inhibition of SGLT proteins: phlorizin is a competitive inhibitor of SGLT1 and SGLT2 but has greater affinity for SGLT2. 5, 20 In the 1980s, a rat model of diabetes was used to demonstrate that phlorizin-induced glucosuria was associated with normalization of plasma glucose without hypoglycemia. 22, 23 Phlorizin also normalized insulin sensitivity in partially pancreatectomized rats but did not affect insulin action in the control animals. 22 The ensuing glucosuria reversed insulin resistance, and discontinuation of phlorizin led to the return of hyperglycemia and insulin resistance. 22 However, phlorizin was unsuitable for clinical development in diabetes due to its poor oral bioavailability: phlorizin is metabolized to phloretin by glucosidase in the gut and, thus, must be given parenterally. Moreover, phloretin is a potent inhibitor of GLUT1, 20 the suppression of which could result in reduced glucose transport to other tissues, such as the central nervous system. 24 Consequently, pharmaceutical research has pursued phlorizin derivatives that possess increased stability/ bioavailability and SGLT2 selectivity, and both O-and C-glucoside entities have been evaluated (Figure 3) . O-glucoside candidates, such as sergliflozin and T-1095, 25 were investigated first, but were discontinued in early clinical development for reasons probably related to nonselective SGLT2 inhibition, 26 and/or bioavailability issues. 27 C-glucoside candidates possessed increased resistance to enzymatic breakdown 28 and have fared more successfully during clinical development with a number of C-glucoside compounds progressing to marketing application and approval.
General characteristics of SGLT2 inhibitors
As the mode of action of SGLT2 is independent of insulin, SGLT2 inhibitors would be expected to act independently of pancreatic beta-cell function and insulin resistance. Consequently, there could be limited loss of potency in SGLT2 inhibitors (ie, maintained glucose lowering effect) when betacell function inevitably deteriorates over time, as is observed with other types of glucose-lowering agents. Furthermore, as inhibition of SGLT2 neither interferes with normal endogenous glucose production in response to hypoglycemia, 29 nor stimulates insulin release, 22, 30 the mode of action of SGLT2 inhibitor therapy should not increase the risk of hypoglycemic episodes. The novel mechanism of action of SGLT2 inhibitor therapy also suggests that it can be given in combination with any of the existing glucose-lowering agents, including insulin, as they share no common mechanistic pathways. 
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Update on SGLT2 inhibitors in diabetes
As well as these predicted benefits, several potential safety issues may be anticipated from the known pharmacodynamic effects of SGLT2 inhibitors. For example, as SGLT2 inhibitors cause a modest osmotic diuresis, there may be a risk of hypotension and hypovolemia; although, lowering of blood pressure (BP) may be of benefit in some individuals with T2DM. The ability of SGLT2 inhibition to increase UGE depends upon the presence of a normal GFR, so the glycemic effectiveness of an SGLT2 inhibitor would be expected to be lower in patients with chronic kidney disease (CKD) and a reduced GFR. The continual presence of glucose in the urine caused by SGLT2 inhibition theoretically increases the risk of urinary tract infections and mycotic genital tract infections. Furthermore, given the renal tubular mechanism of action of SGLT2 inhibitors, this class of compounds has the hypothetical ability to alter the absorption and excretion of calcium and phosphate and, in so doing, potentially affect bone metabolism. Although the various SGLT2 inhibitors in clinical development have a structural similarity, they differ in their respective selectivity profiles for SGLT2 over SGLT1: empagliflozin has the highest degree of selectivity (.2,500-fold), followed by tofogliflozin (.1,875-fold), dapagliflozin (.1,200-fold), ipragliflozin (.550-fold), and canagliflozin (.250-fold). 31 Inhibitors with lower selectivity for SGLT2 versus SGLT1 may incur safety issues arising from SGLT1 inhibition, such as diarrhea caused by glucosegalactose malabsorption. Although, recent data suggest that transient inhibition of SGLT1 by SGLT2 inhibitors may lower postprandial glucose by reducing intestinal glucose absorption.
32
Clinical data from SGLT2 inhibitor trials A summary of SGLT2 inhibitors currently known to be in clinical development is presented in Table 2 . Phase II through IV clinical trials with SGLT2 inhibitors are listed in Table S1 . At the time of writing, dapagliflozin and canagliflozin are marketed in the US and EU and empagliflozin gained recent approval from the European Medicines Agency and the US Food and Drug Administration. Outside of the US and EU marketing applications for ipragliflozin, luseogliflozin, and tofogliflozin were submitted to Japan's Phar- Table S2 . In addition, several fixed dose combination products utilizing SGLT2 inhibitors plus another class of oral anti-diabetes agents are currently in clinical development: dapagliflozin plus metformin (in 5 mg/850 mg and 5 mg/1,000 mg tablets) gained marketing authorization in the EU in early 2014, 33 and single-pill combination products containing dapagliflozin plus saxagliptin, canagliflozin plus metformin, and empagliflozin plus linagliptin or plus metformin, respectively, are in Phase III clinical trials.
The SGLT2 inhibitors currently marketed are indicated as monotherapy for patients with T2DM and inadequate glycemic control from diet and exercise (US and EU indications), [34] [35] [36] [37] who are unable to use metformin (EU-specific), 35, 37 and as an add-on therapy with other glucose-lowering agents, including insulin (EU-specific). 35, 37 In Europe, the recommended dose of dapagliflozin is 10 mg once daily, whether given as a monotherapy or as an add-on therapy combined with other glucose-lowering agents. 35 In the US, the recommended starting dose is 5 mg once daily, which can be increased to 10 mg once daily in patients without renal impairment who tolerate the drug and who require additional glycemic control. 36 The use of dapagliflozin is generally not recommended when eGFR is below 60 mL/min/1.73 m 2 . The recommended starting dose of canagliflozin is 100 mg once daily, which can be increased to 300 mg once daily in patients (without renal impairment) who require additional glycemic control, provided the estimated glomerular filtration rate (eGFR) is 60 mL/min/1.73 m 2 or greater. 34, 37 Canagliflozin is generally not recommended when eGFR is below 45 ml/min/1.73 m 2 . In pre-registration Phase III trials, empagliflozin was independently dosed at 10 mg and 25 mg once daily as monotherapy and as add-on combination therapy to other glucose-lowering agents, including insulin.
Clinical efficacy
A summary of efficacy data from key clinical trials of SGLT2 inhibitors (as registered in ClinicalTrials.gov) that are available, or expected to soon be available, in the US and EU is presented in Table S3 . Selected efficacy data are also presented in Figure 4 . Dapagliflozin, canagliflozin, and empagliflozin are the most advanced of the SGLT2 inhibitors in terms of clinical development, and have the largest amount of published clinical data currently available. Pooled analyses of Phase III study data and data from US and EU regulatory reports were also available for dapagliflozin and canagliflozin, whereas data for empagliflozin were principally obtained from publications of individual Phase III studies. Other SGLT2 inhibitors were earlier in clinical development and had fewer publications available at the time of writing, or had no clinical trials registered in ClinicalTrials.gov due to their current development occurring outside the US.
Glycemic efficacy
Several meta-analyses have demonstrated a significant improvement of glycemic control in patients with T2DM who were treated with SGLT2 inhibitors. [60] [61] [62] The largest of these included data from 58 SGLT2 inhibitor trials, predominantly involving dapagliflozin and canagliflozin, and reported that this drug class had a favorable effect on reducing glycosylated hemoglobin (HbA 1c ; mean difference versus placebo, −0.7% [95% confidence interval {CI} −0.7, −0.6]; mean difference versus active comparator, −0.1% [95% CI −0.2, 0.05]).
60 Dapagliflozin 10 mg provided statistically significant and clinically relevant improvements in glycemic control compared with placebo (with mean placebo-corrected HbA 1c decrease in the different studies ranging from −0.5% to −0.7% at 24 weeks), when given as monotherapy or as add-on therapy to metformin, sulfonylurea, thiazolidinediones, or insulin. 63 As add-on therapy to metformin, dapagliflozin 10 mg was shown to have non-inferior efficacy versus glipizide after 52 weeks.
41 Dapagliflozin 10 mg was also shown to have non-inferior efficacy versus metformin extended release when both were given as monotherapy for 24 weeks. 39 Furthermore, the glucose-lowering effect of dapagliflozin as add-on therapy was maintained over periods of 48-102 weeks. 42, 64, 65 Pooled data for canagliflozin 300 mg and 100 mg gave an overall mean change from baseline in HbA 1c relative to placebo of −0.8% (95% CI −0.9, −0.8) and 0.7% (95% CI −0.75, −0.6), respectively.
66 Individual studies over 52 weeks using canagliflozin as monotherapy, 67 Empagliflozin 10 mg and 25 mg also led to statistically significant and clinically meaningful improvements in HbA 1c . [53] [54] [55] [56] [57] In monotherapy and compared with placebo, adjusted mean differences in change from baseline HbA 1c at week 24 were −0.7% (95% CI −0.9, −0.6; P,0⋅0001) for empagliflozin 10 mg, −0.9% (95% CI −1.0, −0.7; P,0.0001) for empagliflozin 25 
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Update on SGLT2 inhibitors in diabetes A F e r r a n n in i 3 8 S t e n lo f 6 7 F e r r a n n in i 5 5 R o d e n 5 3 N a u c k 4 1 H e n r y 3 9 C e f a lu 4 6 F e r r a n n in i 5 5 S t r o je k 4 0 S c h e r n t h a n e r 4 8 W il d in g 4 9 W il d in g 4 3 M a t t h e w s 5 0 * H ä r in g 5 4 H ä r in g 5 6 R o s e n s t o c k 5 8 Figure 4 (Continued) −0.9, −0.6; P,0⋅0001) for sitagliptin. 53 Placebo-corrected changes in HbA 1c after 24 weeks for empagliflozin added to metformin were −0.6% (95% CI −0.7, −0.4; P,0.001) for empagliflozin 10 mg and −0.6% (95% CI −0.8, −0.5; P,0.001) for empagliflozin 25 mg. 54 Larger reductions in HbA 1c were observed in patients with higher baseline levels of HbA 1c for each of these three SGLT2 inhibitors. 38, 45, 53 Changes in HbA 1c and fasting plasma glucose from individual key trials using dapagliflozin, canagliflozin, and empagliflozin are presented in Table S3 . F e r r a n n i n i 3 8 S t e n l o f 6 7 F e r r a n n i n i 5 5 R o d i n 5 3 N a u c k 4 1 H e n r y 3 9 C e f a l u 4 6 H ä r i n g 5 4 F e r r a n n i n i 5 5 S t r o j e k 4 0 S c h e r n t h a n e r 4 8 W i l d i n g 4 9 H ä r i n g 5 The effect was maintained over 102 weeks in a study of dapagliflozin 10 mg added to metformin therapy, with a body weight reduction −4.5 kg versus −2.1 kg for placebo plus metformin. 68 Dual-energy X-ray absorptiometry revealed this reduction in body weight was principally due to a reduction in body fat mass, rather than a loss of fluid or lean tissue. 68 For canagliflozin, the change in body weight from baseline was generally consistent across placebo-controlled 
Changes in body weight and composition
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Update on SGLT2 inhibitors in diabetes Phase III studies, but was lower where sulfonylurea was a background therapy: the US Food and Drug Administration (FDA) briefing document stated the placebo-subtracted mean reduction in body weight (excluding sulfonylurea background) was −1.8% to −3.8% for the 300 mg dose and −1.6% to −2.4% for the 100 mg dose. 69 For empagliflozin monotherapy, mean placebo-corrected changes in body weight from baseline after 24 weeks were −1.9 kg (95% CI −2.4, −1.4; P,0.0001) and −2.1 kg (95% CI −2.6, −1.7; P,0.0001) for 10 mg and 25 mg groups, respectively, versus 0.5 kg (95% CI 0.04, 1.0; P=0.0355) for the sitagliptin comparator group. 53 When empagliflozin was added to metformin the mean change in body weight after 24 
60
A decrease in systolic BP was observed consistently across the dapagliflozin studies (Table S3) . 63 In a small study (n=75) directly comparing dapagliflozin with an antihypertensive, treatment with placebo, dapagliflozin (10 mg/day), or hydrochlorothiazide (25 mg/day) resulted in adjusted changes from baseline in 24-hour ambulatory mean systolic BP of −0.9 (95% CI −4.2, 2.4), −3.3 (95% CI −6.8, 0.2), and −6.6 (95% CI −9.9, −3.2) mmHg, respectively, at week 12. 70 The study data suggest that dapagliflozin may have a diuretic-like capacity to lower BP in addition to beneficial effects on glycemic control.
70
Canagliflozin demonstrated a dose-dependent and significant placebo-subtracted mean reduction in systolic BP, except when used as an add-on to sulfonylurea, ranging from 2.6-5.7 mmHg and 3.5-7.9 mmHg for the 100 mg and 300 mg doses, respectively. 69 This was supported by a recent pooled analysis of six Phase III studies (n=4,158) using canagliflozin, in which modest reductions in systolic BP were observed relative to placebo (−3.3 and −4.5 mmHg for 100 mg and 300 mg, respectively).
71
A pooled analysis of data from four Phase III trials (n=2,477) investigating empagliflozin 10 mg or 25 mg given for 24 weeks as monotherapy or as add-on therapy (with metformin, or metformin plus sulfonylurea, or pioglitazone ± metformin) reported reductions in systolic blood pressure (SBP) for empagliflozin groups versus placebo (placebo-corrected change from baseline −3.4 mmHg and −3.8 mmHg for empagliflozin 10 mg and 25 mg, respectively). 72 A study of patients (n=823) with T2DM and hypertension found that empagliflozin 10 mg and 25 mg significantly reduced mean 24 hour SBP, measured via ambulatory BP monitoring, versus placebo (−2.95 and −3.68 mmHg versus 0.48 mmHg, respectively; P,0.001 versus placebo for each dose).
73
Clinical safety
As defined for Table S3 , a summary of safety data from key clinical trials of SGLT2 inhibitors is presented in Table S4 and selected safety data are presented in Figure 4 .
Urinary tract infections and genital tract infections
In a meta-analysis of eight studies using canagliflozin and dapagliflozin that compared the SGLT2 inhibitors with other anti-diabetes agents, urinary tract infections were more common with SGLT2 inhibitors (odds ratio, 60 Safety data from a pooled retrospective analysis of data from the short-term, double-blind periods of 12 placebo-controlled trials (n=4,545) using dapagliflozin reported that genital tract infections and lower urinary tract infections were more common with dapagliflozin than placebo; however, between-group differences were less marked for urinary tract infections (genital tract infection 4.1%-5.7% dapagliflozin versus 0.9% placebo; urinary tract infection 3.6%-5.7% dapagliflozin versus 3.7% placebo).
74,75
Similar findings were reported from pooled analyses of canagliflozin and empagliflozin.
A pooled analysis of four 26 week Phase III studies (n=2,313) of canagliflozin found higher proportions of subjects with urinary tract infections and genital tract infections occurred in the canagliflozin groups than with placebo (urinary tract infection 5.1% canagliflozin versus 4.0% placebo; genital tract infection 7.5% canagliflozin versus 1.9% placebo).
76,77
A pooled analysis of four Phase III studies (n=2,477) using empagliflozin found that empagliflozin was associated with an increased frequency of genital tract infections compared with placebo (approximately 4% versus 1%, respectively), but this was not the case for urinary tract infections (frequency of approximately 8%-9% for each).
78
For dapagliflozin, canagliflozin, and empagliflozin studies, events of genital tract infections and urinary tract infections were more common in women than in men in all treatment groups (Table S4) Similar findings were observed with canagliflozin, with a low risk of hypoglycemia among subjects treated with canagliflozin taken as monotherapy, or in combination with other anti-hyperglycemic agents not associated with hypoglycemia. An increased incidence of hypoglycemia was observed when canagliflozin was used in combination with insulin or sulfonylureas. 34, 49, 50 The prescribing information for both canagliflozin and dapagliflozin recommend using a lower dose of insulin or insulin secretagogue to reduce the risk of hypoglycemia when used in combination with the respective SGLT2 inhibitor. 34, 36 The rate of hypoglycemia was also low with empagliflozin monotherapy and was comparable to placebo.
53
For empagliflozin added to metformin plus sulfonylurea, the frequency of confirmed hypoglycemia was greater for empagliflozin versus placebo, but none of these events required assistance. 56 When empagliflozin was added to basal insulin, no increased risk of hypoglycemia was reported versus placebo.
58
Renal safety and volume depletion events
Approximately 375 mL of extra urinary volume is produced per day with dapagliflozin 10 mg therapy. 35 A pooled safety analysis of dapagliflozin using data from the double-blind periods of 12 placebo-controlled trials (n.4,500) reported that volume depletion events occurred in 0.6%-1.2% for dapagliflozin groups (2.5-10 mg) versus 0.4% for placebo groups, 79 indicating a slightly elevated risk and a need to maintain an adequate fluid intake. Hypotension occurred more frequently in dapagliflozin-treated groups than placebo groups for subjects who were elderly, had moderate renal impairment, or were treated with loop diuretics. 63 Dapagliflozin treatment was not associated with increased risk of acute renal toxicity or deterioration of renal function. 80 The estimated GFR (eGFR) decreased initially then returned to baseline by week 24 and was maintained to week 102, while mean serum creatinine showed minimal change (± 0.01 mg/dL) from baseline to week 24 in all groups. 80 As a safety measure, the dapagliflozin Summary of Product Characteristics recommends against its use in patients receiving loop diuretics or who are volume depleted, or who have moderate to severe renal impairment (defined as patients with creatinine clearance ,60 mL/min or eGFR ,60 mL/min/1.73 m 2 ), and encourages monitoring of volume status in cases where intercurrent conditions could lead to volume depletion. 35 A 104-week Phase III study of dapagliflozin treatment in T2DM patients with moderate renal impairment reported events of renal impairment or renal failure were uncommon (2.4% and 9.4% for dapagliflozin 5 mg and 10 mg, respectively; 7.1% for placebo), and volume depletion events were more frequent with dapagliflozin (9.6% and 12.9% for dapagliflozin 5 mg and 10 mg, respectively; 6.0% for placebo).
44
Analysis of a pooled dataset from the canagliflozin FDA briefing document stated that volume depletion-related adverse events, most commonly hypotension, occurred in 1.2% and 1.3% of canagliflozin 100 mg and 300 mg groups, respectively, versus 1.1% in placebo groups; 69 furthermore, none of these events in the canagliflozin groups were serious or led to study discontinuation. 69 In a pooled analysis of eight clinical trials (placebo-and active-controlled), volume depletion-related adverse events occurred in 2.3% and 3.4% of canagliflozin 100 mg and 300 mg groups, respectively, versus 1.5% in the comparator groups. 34 Risk factors for these events were similar to those identified for dapagliflozin (eg, patient's age $75 years, eGFR ,60 mL/min/1.73 m 2 , and use of loop diuretics). 34 A Phase III trial of canagliflozin use in T2DM patients with stage 3 CKD (eGFR $30 and ,50 mL/min/1.73 m 2 ) reported larger decreases in eGFR from baseline in canagliflozin treatment groups (least square mean change, −9.1% and −10.1% for 100 mg and 300 mg, respectively, versus −4.5% for placebo). 51 The reductions in eGFR with canagliflozin were largest at week 3 (the first post-baseline measurement) and then returned back toward baseline over the 26-week treatment period. 
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Update on SGLT2 inhibitors in diabetes and 300 mg groups progressed to albuminuria (ie, from normoalbuminuria to micro-or macro-albuminuria, or from micro-to macro-albuminuria) versus those in the placebo group ( 
51
A pooled analysis of empagliflozin data (.11,000 T2DM patients from Phase I, II, and III trials) reported that the percentage of patients with volume depletion events was similar with empagliflozin (10 mg dose group 1.4%; 25 mg dose group 1.5%) and placebo (1.4%). 81 More patients receiving diuretics reported these events than those not receiving diuretics (2.2%-2.7% versus 0.9%-1.0%, respectively). . 59 In patients with stage 2, 3, or 4 CKD, small decreases in eGFR were noted in the empagliflozin groups, which returned to baseline by the end of the 3 week follow-up after treatment completion. 59 In patients with stage 3 CKD, fewer patients on empagliflozin 25 mg than placebo shifted from no albuminuria at baseline to microalbuminuria, or from microalbuminuria at baseline to macroalbuminuria, at end of treatment (12.2% with empagliflozin versus 22.2% with placebo, and 2.0% with empagliflozin versus 11.4% with placebo, respectively).
59
Venous thromboembolic events
As volume depletion may increase the risk of hemoconcentration and venous thromboembolism (VTE), VTE events were monitored in trials using SGLT2 inhibitors.
Patients receiving dapagliflozin had a similar rate of VTE events to those in the comparator group (0.3% for both groups). 63 For canagliflozin, the rate of VTE in Phase III trials was also low (0.2% and 0.3% for canagliflozin 100 mg and 300 mg groups, respectively, versus 0.2% for non-canagliflozin groups).
69 VTE data have not yet been reported for empagliflozin.
82,83
Bone safety
There was no clear evidence that dapagliflozin induced bone demineralization or increased fracture rates in people with diabetes and normal or mildly impaired renal function (eGFR .90 mL/min/1.73 m 2 and $60 to ,90 mL/ min/1.73 m 2 , respectively), 63,84 but bone fractures were more common in dapagliflozin-treated patients with moderate renal impairment (eGFR .30 to ,60 mL/min/1.73 m 2 ; 4.8% and 9.4% for 5 mg and 10 mg groups, respectively, versus 0% for placebo-treated subjects). 63 A 102 week study (n=140) did not identify any meaningful changes from baseline in markers of bone turnover or bone mineral density in patients receiving dapagliflozin added to metformin, when compared with placebo. 68 No meaningful changes in bone density were observed with canagliflozin treatment over 26 weeks, according to the FDA briefing report, 69 but there was an increase in overall bone fracture events with canagliflozin (2.5% for 100 mg and 2.3% for 300 mg) compared to control (1.7%; includes placebo and active comparators, both with various background therapies). A 104-week trial (26-week double-blind phase + 78-week double-blind extension phase) evaluating canagliflozin in older patients (aged 55-80 years) with T2DM (ClinicalTrials.gov identifier: NCT01106651) included an assessment of bone density, which will be reported separately from the main efficacy/safety analysis. 52 However, no discernible changes in bone density were observed at 26 weeks. 85 In a pooled analysis of data from more than 11,000 patients with T2DM from Phase I, II, and III trials, empagliflozin was not associated with an increased frequency of bone fractures versus placebo (1.6% and 1.1% for empagliflozin 10 mg and 25 mg, respectively, versus 1.6% for placebo).
86
Cardiovascular safety SGLT2 inhibitors have favorable effects on cardiovascular (CV) risk factors by reducing hyperglycemia, body weight, and BP, 87 but changes in lipid profiles have caused some concern, 88 and information on major CV outcomes such as stroke, heart attack, and other vascular complications is currently limited.
89 Several large, long-term studies with CV endpoints are ongoing and will provide data in the next 2-6 years (Table 3) . 90, 91 Results from a meta-analysis on CV outcomes and death with SGLT2 inhibitors showed overall no evidence for an increased CV risk with SGLT2 inhibitor treatment. 60 The EMA assessment report on dapagliflozin stated that an independently confirmed meta-analysis of Phase IIb/III studies did not show an increased CV risk in dapagliflozin-treated patients. 63 The estimated hazard ratio 
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Nauck for the primary composite endpoint (time to first event of the following adjudicated events: CV death, myocardial infarction, stroke, and hospitalization for unstable angina) using a Cox proportional hazards method was 0.674 (95% CI 0.421, 1.078). 63 Similarly, a meta-analysis to assess CV safety for canagliflozin was presented in the FDA report, 69 and included all Major Adverse Cardiovascular Events Plus (MACE-Plus; defined as a composite endpoint consisting of the following adjudicated events: CV death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for unstable angina) in nine Phase III trials (including interim data from the canagliflozin cardiovascular assessment study [CANVAS] ). The estimated hazard ratio was 0.91 (95% CI 0.68, 1.22) for the risk of MACE-Plus comparing canagliflozin to all comparators (via the pre-specified primary Cox proportional hazards model fit to all trials including CANVAS).
69
Changes in lipid profiles observed with SGLT2 inhibitor therapy have caused some concern.
88 Dose-related increases in low-density lipoprotein cholesterol (LDL-C) were observed with canagliflozin, as shown in a pooled analysis of data from four 26-week placebo-controlled trials in which the mean percentage increases from baseline in LDL-C were 4.5% and 8.0% for 100 mg and 300 mg canagliflozin, respectively, relative to placebo. 92 Canagliflozin labeling information recommends LDL-C should be monitored and treated according to standard care after initiating canagliflozin therapy.
92
Statistically significant increases in high-density lipoprotein 
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Update on SGLT2 inhibitors in diabetes cholesterol (HDL-C) from baseline were observed with canagliflozin in four of eight placebo-controlled Phase III trials, but decreases in triglyceride levels with canagliflozin were small and were generally not statistically significant.
93
For patients receiving dapagliflozin in Phase III trials, overall small mean changes in HDL-C (+2.1% to +9.3%), triglyceride (−0.9% to −10.6%), and LDL-C (−0.5% to +9.5%) were observed, but there was no clinically significant effect on lipid levels in the individual dapagliflozin studies concerned. 94 For empagliflozin, a pooled analysis of four placebo-controlled Phase III trials reported small increases in HDL-C and LDL-C and small decreases in triglycerides with empagliflozin versus placebo after 24 weeks.
72
Malignancies A pooled analysis of data for all dapagliflozin doses from 19 Phase IIb/III trials revealed that the incidence rates for malignancies were similar for dapagliflozin (1.4%) and placebo/comparator (1.3%), 79 and there was no carcinogenicity or mutagenicity signal in animal data. 35 However, breast and bladder cancer adverse events were numerically greater with dapagliflozin than placebo/comparator. 35, 63, 79, 95 The US prescribing information for dapagliflozin states that the drug should not be used in patients with active bladder cancer and should be used with caution in patients with a history of this disease. 36 Furthermore, the dapagliflozin Summary of Product Characteristics does not recommend the use of dapagliflozin in patients being treated with pioglitazone, as epidemiological data suggest a small increased risk of bladder cancer with pioglitazone. 35 Adverse events for breast and bladder cancer, plus renal cell cancer, were also monitored in the clinical studies for canagliflozin. 69 The incidences of these tumor events were low and they occurred at a similar rate across treatment groups (breast cancer 0.38%-0.46% versus 0.4%; bladder cancer 0.06%-0.09% versus 0.11%; renal cell cancer 0.06%-0.09% versus 0.08% for canagliflozin 100 mg and 300 mg groups versus non-canagliflozin groups, respectively). 69 No data on malignancy rates from trials using empagliflozin (or any of the other SGLT2 inhibitors) have been reported to date. Nevertheless, these safety signals raised concerns and further data are required to exclude the possibility of an elevated risk of certain types of cancer occurring with SGLT2 inhibitor treatment.
Current and future roles for SGLT2 inhibitors
Currently available published clinical trial data for SGLT2 inhibitors document their use as add-on therapy with metformin, insulin, sulfonylureas, dipeptidyl peptidase (DPP-4) inhibitors, or thiazolidinediones. SGLT2 inhibitors may also have a role as monotherapy; for example, in patients who are intolerant to metformin due to ensuing gastrointestinal side effects. Data from published trials indicate that various SGLT2 inhibitors have a similar ability to improve glucose control with a low risk of hypoglycemia, together with promoting modest reductions in BP and body weight. The properties of SGLT2 inhibitors present for the first time the possibility of a triple combination (ie, metformin, DPP-4 inhibitor, and SGLT2 inhibitor), with the expected net effect of weight reduction and freedom from hypoglycemic episodes. This could be particularly attractive in Europe, where triple oral combinations have not been popular (presumably, because at least one of the combination components introduced undesired adverse events, such as weight gain and/or hypoglycemia). At present, there is no evidence suggesting preference of any one SGLT2 inhibitor over another: any differences between individual SGLT2 inhibitors may be revealed when clinical head-to-head comparator studies are carried out, although no such studies are currently reported to be underway. A Phase I study comparing the pharmacodynamics of canagliflozin and dapagliflozin was recently completed and publication of the data is awaited (ClinicalTrials.gov identifier: NCT01877889), the primary outcome measure was the between-treatment difference in 24-hour mean renal threshold for glucose.
The effect of SGLT2 inhibition on preserving beta-cell function and improving insulin sensitivity has also been reported. Data from a study using an insulin-resistant animal model of T2DM found that sustained glucose lowering with dapagliflozin improved insulin sensitivity and pancreatic islet function and morphology. 96 The authors suggested that reduction of hyperglycemia by dapagliflozin, through an insulin-independent mechanism, may improve core defects present in T2DM; however, further research is needed before firm conclusions can be drawn. 96 Recently published and independent studies using dapagliflozin and empagliflozin in patients with T2DM reported increased insulin sensitivity following SGLT2 inhibitor therapy, 97,98 and empagliflozininduced UGE also improved beta-cell function.
98 SGLT2 inhibition with either of these agents increased to some extent endogenous glucose production, despite reducing fasting plasma glucose, and this may be at least partially explained by concentration change in the insulin to glucagon ratio which has been observed with SGLT2 inhibitor therapy. 89, 90 There is also preliminary evidence to suggest that SGLT2 inhibitors with lower selectivity towards SGLT1 (ie, canagliflozin) 
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Nauck achieve intra-intestinal levels after oral dosing that may be sufficiently high to transiently inhibit intestinal SGLT1 and reduce intestinal glucose absorption, 32, 99 resulting in increased release of glucagon-like peptide-1 and peptide YY. 32 ,100 These factors together may make SGLT2 inhibitors an attractive choice for T2DM patients who are failing with metformin and who need to lose weight.
Furthermore, SGLT2 inhibitors may have the potential to be used as an insulin-sparing agent in T2DM patients using insulin.
43,58,64 A long-term study of dapagliflozin in T2DM patients using insulin reported the mean insulin dose increased by 18.3 IU/day and body weight increased by 1.8 kg in the placebo group after 104 weeks, whereas insulin dose was stable and body weight decreased by 0.9 kg in the dapagliflozin groups. 64 A similar trend was reported after 78 weeks of empagliflozin treatment.
58 SGLT2 inhibitors could possibly be used transiently instead of insulin treatment in patients who are otherwise well controlled but who develop temporary acute hyperglycemia, due to factors such as short-term immobility, infectious diseases, etc. Additionally, SGLT2 inhibitors may have a role in improving glucose tolerance in pre-diabetic individuals. However, to allow the use of these agents in patients without established disease, clinical trials with SGLT2 inhibitors would need to show a reduced risk for relevant clinical endpoints (eg, CV, etc) as well as robust safety data.
Pilot studies using SGLT2 inhibitors in patients with T1DM are also in progress (ClinicialTrials.gov identifiers: NCT01498185, NCT01392560, NCT01742208), and preliminary results have been presented. 101, 102 A further possible use of SGLT2 inhibitors in T1DM is the concept that SGLT2 inhibition may have renal effects by lowering intra-glomerular pressure, which has recently been demonstrated with empagliflozin in patients with T1DM. 103 This observation could explain the reduction of albuminuria with SGLT2 treatment described in Phase III studies. In addition, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE; ClinicialTrials.gov identifier: NCT02065791) study has just commenced, and is a renal outcome study to investigate whether SGLT2 inhibition has renal potential beyond its glucose-lowering properties.
As a final point, it is of interest to note that current SGLT2 inhibitors only inhibit 30%-50% of the filtered glucose load, ie, 50-80 g of the ∼180 g filtered per day. The possible pharmacokinetic reasons for this imbalance are discussed in a report by Liu et al, 104 and a novel hypothesis to explain this conundrum was recently postulated by Abdul-Ghani et al. 105 Namely, complete inhibition of SGLT2 causes SGLT1 to reabsorb glucose at full capacity; therefore, only the fraction of filtered glucose that escapes SGLT1 will be excreted in the urine. 105 A better understanding of renal SGLT2 inhibitor handling may help to develop future agents that can inhibit a larger proportion of filtered glucose and further reduce HbA 1c levels, 104 for example, agents with the capacity to also partially inhibit renal SGLT1 and produce a more vigorous UGE than those that are highly specific for SGLT2 inhibition only. 105 There is potentially much more to come from this novel class of drugs, and we wait with interest to see what further developments and therapeutic applications may arise.
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Update on SGLT2 inhibitors in diabetes Table S2 SGLT2 and SGLT1 inhibitors currently in the development pipeline It has been investigated in monkeys, where it triggered glucosuria in a dose-dependent manner, and in obese diabetic rats, where it normalized diabetes and reduced blood glucose by 48% compared to the non-treated group.
http://www.sironabiochem.com/sironabiochem-announces-preclinical-resultsof-diabetes-compound-2/ N-glucoside 9d
Mitsubishi Tanabe Preclinical A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50=7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles.
Yamamoto et al
33
LX2761
Lexicon Preclinical LX2761, an SGLT1 inhibitor restricted to the intestine, improves glycemic control in mice.
Powell et al 34 
KGA2727
GlaxoSmithKline Preclinical Synergistic glucose-lowering effects of SGLT1-and apical sodium-dependent bile acid transporter-inhibitor (GSK2299027) combinations in Zucker-fatty diabetic rats.
Young et al 35 
6-Deoxydapagliflozin
None stated Preclinical Systematic mono-deoxylation of the four hydroxyl groups in the glucose moiety in dapagliflozin led to the discovery of 6-deoxydapagliflozin 1 as a more active sodiumdependent glucose co-transporter 2 (SGLT2) inhibitor (IC50=0.67 nM against human SGLT2 (hSGLT2) versus 1.16 nM for dapagliflozin). It exhibited more potent blood glucose inhibitory activity in rat oral glucose tolerance test and induced more urinary glucose in rat urinary glucose excretion test than its parent compound dapagliflozin.
Zhang et al 36
Abbreviations: SGLT, sodium glucose co-transporter; IND, investigational new drug; IC50, half minimal inhibitory concentration; UGE, urinary glucose excretion.
Drug Design, Development and 
−24
−27
−84 61 −1. a Data are presented as published (from randomized double-blind arms of each trial unless otherwise stated). Abbreviations: AHA, anti-hyperglycemic agent; AM, ante meridiem (in the morning); BD, bis in die (twice per day); BG, blood glucose; BMI, body mass index; CANTATA, canagliflozin treatment and trial analysis; CANTATA-D2, dipeptidyl peptidase 4 inhibitor second comparator; CANTATA-M, metformin; CANTATA-MSU, metformin + sulfonylurea; CANTATA-SU, sulfonylurea; CANVAS, canagliflozin cardiovascular assessment study; CKD, chronic kidney disease; DAPA, dapagliflozin; DDP4, dipeptidyl peptidase 4; EMPA, empagliflozin; F, female; GenI, genital infection; GLIM, glimepiride; GLIP, glipizide; HbA 1c (or A 1c ), glycated hemoglobin; INS, insulin; M, male; MedDRA PT, Medical Dictionary for Regulatory Activities Preferred Terms; MET, metformin; NCT ID, National Clinical Trials (US) identification (number); OAD, oral anti-diabetes drug; O/L, open label; Pbo, placebo; PG, plasma glucose; PIO, pioglitazone; PM, post meridiem (in the afternoon); SGLT2, sodium glucose co-transporter type 2; SITA, sitagliptin; SU, sulfonylurea; TZD, thiazolidinedione; UTI, urinary tract infection; VVAE, vulvovaginal adverse event; XR, extended release formulation.
